Stockreport

Ocugen outlines plans for three BLA filings in next three years amid global gene therapy expansion [Seeking Alpha]

Ocugen, Inc.  (OCGN) 
PDF CEO Shankar Musunuri highlighted the company's rapid progress on its modifier gene therapy platform, noting "in just over 3 years, we brought our lead candidate, OCU400 [Read more]